JP2024540836A5 - - Google Patents

Info

Publication number
JP2024540836A5
JP2024540836A5 JP2024520616A JP2024520616A JP2024540836A5 JP 2024540836 A5 JP2024540836 A5 JP 2024540836A5 JP 2024520616 A JP2024520616 A JP 2024520616A JP 2024520616 A JP2024520616 A JP 2024520616A JP 2024540836 A5 JP2024540836 A5 JP 2024540836A5
Authority
JP
Japan
Prior art keywords
fut5
crlf1
psp
mmp
capture reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045989 external-priority patent/WO2023059854A1/en
Publication of JP2024540836A publication Critical patent/JP2024540836A/ja
Publication of JP2024540836A5 publication Critical patent/JP2024540836A5/ja
Pending legal-status Critical Current

Links

JP2024520616A 2021-10-07 2022-10-07 肺癌の予測及びその利用 Pending JP2024540836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253509P 2021-10-07 2021-10-07
US63/253,509 2021-10-07
PCT/US2022/045989 WO2023059854A1 (en) 2021-10-07 2022-10-07 Lung cancer prediction and uses thereof

Publications (2)

Publication Number Publication Date
JP2024540836A JP2024540836A (ja) 2024-11-06
JP2024540836A5 true JP2024540836A5 (enExample) 2025-10-03

Family

ID=84329604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520616A Pending JP2024540836A (ja) 2021-10-07 2022-10-07 肺癌の予測及びその利用

Country Status (5)

Country Link
US (1) US20240393337A1 (enExample)
EP (1) EP4413372A1 (enExample)
JP (1) JP2024540836A (enExample)
CA (1) CA3233138A1 (enExample)
WO (1) WO2023059854A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250111943A1 (en) * 2023-09-28 2025-04-03 Thriva Limited Method for Evaluating Biomarkers in a Biological Sample

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS

Similar Documents

Publication Publication Date Title
Yekula et al. From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers
US10408847B2 (en) Tuberculosis biomarkers and uses thereof
Leligdowicz et al. Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection
KR20180123978A (ko) 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
JP2018504609A5 (enExample)
Jin et al. Development and validation of apolipoprotein AI-associated lipoprotein proteome panel for the prediction of cholesterol efflux capacity and coronary artery disease
Cheng et al. New markers in pneumonia
AU2014331070B2 (en) Kidney disease biomarker
Lavatelli et al. Biochemical markers in early diagnosis and management of systemic amyloidoses
WO2016007549A1 (en) Biomarker signatures for lyme disease and methods of use thereof
JP2014512014A (ja) 川崎病の診断マーカーおよび治療標的
Kawasaki et al. Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19
JP2024540836A5 (enExample)
EP3165926A1 (en) Method for characterization of cell specific microvesicles
Wilson et al. Point-of-care biomarker assay for rapid multiplexed detection of CRP and IP-10
Park et al. In silico molecular docking validation of procalcitonin-binding aptamer and sepsis diagnosis
US20220283157A1 (en) Multiplexed assay kits for evaluation of systemic lupus erythematosus
Luo et al. Association of plasma proteomics with mortality in individuals with and without type 2 diabetes: Results from two population-based KORA cohort studies
CN116298234B (zh) 用于双相障碍区分和鉴别诊断的生物标记物
JP2010528306A (ja) 心筋梗塞の早期予測因子としてのｈ−ｆａｂｐ
JP5307141B2 (ja) 心筋梗塞の早期予測因子としてのミオグロビン
KR102475926B1 (ko) 전신 홍반성 루푸스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루푸스 진단에 필요한 정보를 제공하는 방법
WO2019053124A1 (en) PROADRENOMEDULINE AS AN INDICATOR FOR RENAL REPLACEMENT THERAPY IN SERIOUSLY PATIENT PATIENTS
JP2023156159A5 (enExample)
Silverstein et al. Mitochondrial gene signatures illuminate mitochondrial function as an important contributor to post-COVID recovery and long COVID progression